1. Prognostic significance of the chemokine CXCL13 in node-negative breast cancer
- Author
-
Gert Naumann, Leonie van de Sandt, Marcus Schmidt, Christine Solbach, Marco Johannes Battista, Jan G. Hengstler, Antje Lebrecht, Ralph M. Wirtz, Joerg Rahnenfuehrer, Isabel Sicking, and D. Boehm
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemokine ,Microarray ,biology ,business.industry ,Mrna expression ,Obstetrics and Gynecology ,Chemotaxis ,medicine.disease ,Node negative ,Breast cancer ,Internal medicine ,Maternity and Midwifery ,Immunology ,Cancer research ,biology.protein ,Medicine ,CXCL13 ,business - Abstract
615 Background: The chemokine CXCL13 is chemotactic for B cells. We examined the prognostic significance of CXCL13 mRNA expression in node-negative breast cancer. Methods: Microarray based gene-expression data for CXCL13 (205242_at) were analysed in four previously published cohorts (Mainz, Rotterdam, Transbig, Yu) of node-negative breast cancer patients not treated with adjuvant therapy (n=824). A meta-analysis of previously published cohorts was performed using a random effects model. Prognostic significance of CXCL13 on metastasis-free survival (MFS) was examined in the whole cohort and in different molecular subtypes (ER+/HER2-, ER-/HER2-, HER2+). Independent prognostic relevance was analysed using multivariate Cox regression. Results: Higher RNA expression of CXCL13 was related to better MFS in a meta-analysis of the whole cohort (HR 0.88, 95% CI 0.83-0.94, P
- Published
- 2016
- Full Text
- View/download PDF